MAG3 Renal Scintigraphy & Upper Tract Nuclear Imaging

Quick Reference

Parameter	Threshold	Clinical Meaning
Split renal function (SRF)	<40% ipsilateral	Functionally significant asymmetry
SRF action threshold	<35% and declining	Strong indication to intervene
T½ drainage — normal	<10 min	Unobstructed
T½ drainage — equivocal	10–20 min	Repeat or augment with clinical data
T½ drainage — obstructed	>20 min	Mechanical obstruction pattern
Neurogenic bladder pressure threshold	40 cmH₂O (end-fill)	McGuire threshold — upper tract risk
Furosemide dose (adult)	0.5 mg/kg IV (max 40 mg)	Standard diuresis challenge

---

1. Radiopharmaceutical: Tc-99m MAG3

Chemistry and Mechanism

Technetium-99m mercaptoacetylglycylglycylglycine (Tc-99m MAG3) is cleared predominantly by proximal tubular secretion via organic anion transporters (OAT1/OAT3) — the same pathway as para-aminohippurate (PAH). Approximately 90% of circulating MAG3 is protein-bound to albumin, limiting glomerular filtration. Effective renal plasma flow (ERPF) extraction fraction is ~40–50% per pass, compared to <20% for DTPA.

Key physical properties:

• Photon energy: 140 keV (Tc-99m decay)
• Physical half-life: 6.02 hours
• Biological half-life: 2–3 hours (renal elimination)
• Effective dose: ~1.5–2.5 mSv (adult, standard 185 MBq dose)

Why Tubular Secretion Matters

In patients with reduced GFR — common in reconstructive urology patients with chronic obstruction — glomerular filtration falls disproportionately. MAG3 tubular secretion is preserved until late-stage renal failure, yielding usable renogram curves where DTPA produces a flat, uninterpretable study. This is why MAG3 has replaced DTPA as the default agent for upper tract functional evaluation in reconstructive urology.

---

2. The Renogram Curve: Three Phases

The renogram is a time-activity curve plotting counts from each renal region-of-interest (ROI) vs. time. Standard acquisition: 20–30 minutes, extended to 45–60 minutes with diuretic phase.

Phase 1: Perfusion/Vascular (0–60 seconds)

Rapid bolus injection produces simultaneous aortic and renal perfusion peaks. Renal-to-aortic ratio at peak reflects relative perfusion. Asymmetry >20% between kidneys suggests arterial disease, severe parenchymal loss, or obstructive cortical thinning.

Phase 2: Functional/Uptake (1–3 minutes)

Curve rises as tubular cells extract MAG3 from blood. Slope and height reflect functional renal mass and ERPF. Time to peak activity (Tmax) is normally 3–5 minutes; prolonged Tmax (>6–8 minutes) or a flat curve indicates parenchymal dysfunction.

Split renal function is calculated from Phase 2 counts (typically at 1–2 minutes post-injection), not from the drainage phase.

Phase 3: Excretory/Drainage (3–20+ minutes)

After peak uptake, MAG3 is excreted into the collecting system. Normal: smooth decay reaching half-peak within 10 minutes of furosemide (see Section 3).

Renogram Curve Pattern Classification (O'Reilly–Whitaker)

Pattern	Curve Shape	Interpretation
Type 1 (Normal)	Sharp rise, smooth fall to baseline	Unobstructed, good function
Type 2 (Obstructed)	Rise, plateau, no fall	High-grade mechanical obstruction
Type 3a (Equivocal)	Rise, partial fall — washes out with diuretic	Dilated but not obstructed
Type 3b (Obstructed)	Rise, continues to rise or plateau despite diuretic	Mechanical obstruction confirmed
Type 4 (Poor function)	Flat or minimal rise	Severely reduced function — split function unreliable

---

3. Diuretic Renogram Protocol

Rationale

A dilated collecting system can produce an obstructed-appearing renogram simply from pooling in a large capacitance pelvis without true mechanical obstruction. IV furosemide forces high urine flow, washing out tracer rapidly in an unobstructed system but failing to do so against a true mechanical obstruction. The half-time of washout (T½) quantifies the response.

Furosemide Timing Protocols

F+20 — Standard Protocol (Recommended)

Furosemide injected 20 minutes after radiopharmaceutical. Most widely used and best-validated protocol, recommended by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and British Nuclear Medicine Society (BNMS). The collecting system is pre-loaded with tracer before the diuresis challenge, making drainage measurement most reproducible.

• Adult dose: 0.5 mg/kg IV, max 40 mg
• Pediatric dose: 1 mg/kg IV, max 40 mg

F−15 — "Well-Tempered" Protocol

Furosemide given 15 minutes before tracer injection. Pre-loads diuresis, eliminating the risk of a poorly hydrated patient failing to respond at F+20. Preferred for large capacitance pelves or patients with previous equivocal F+20 studies. Limitation: peak diuresis may occur during Phase 2, potentially underestimating split renal function.

F0 — Simplified Protocol

Furosemide and tracer given simultaneously. Faster and simpler, but less physiologically rigorous. Acceptable for straightforward clinical questions; avoid when precise SRF is the primary endpoint.

Hydration Requirements

Step	Requirement
Pre-procedure oral hydration	500 mL water 30 minutes before study
IV hydration (optimal)	7 mL/kg (up to 500 mL) NS over 30 min before injection
Bladder catheter	Mandatory if bladder outlet obstruction or neurogenic bladder; strongly recommended for all adult studies

:::warning Bladder Drainage Is Critical A full bladder raises collecting system back-pressure and converts an unobstructed drainage curve into an obstructed-appearing one. Always catheterize or ensure complete voiding before and during the study in patients with BOO or neurogenic bladder. :::

Conditions That Confound Diuretic Renogram Interpretation

Confounder	Effect	Solution
Dehydration	Falsely prolonged T½	Ensure adequate hydration per protocol
Diuretic resistance (CKD, hepatic disease)	Inadequate diuresis — T½ unreliable	Note on requisition; consider F−15
SRF <15%	Washout unreliable regardless of obstruction	Report T½ with caveat; use clinical + imaging correlation
Massive hydronephrosis	Giant capacitance pelvis dilutes diuretic effect	F−15 protocol preferred
Recent iodinated contrast (<48 h)	Competes with MAG3 at OAT transporters — reduces tubular uptake	Delay MAG3 48 hours after CT urogram

T½ Interpretation

T½ (from furosemide injection)	Interpretation	Clinical Action
<10 minutes	Unobstructed drainage	No intervention needed on drainage basis
10–20 minutes	Equivocal	Repeat after optimized hydration; correlate with SRF trend and symptoms
>20 minutes	Obstructed pattern	Surgical correction indicated (pyeloplasty, ureterolysis, stent)

---

4. Split Renal Function (SRF)

Calculation

SRF is derived from Phase 2 uptake window counts (typically 1–2 min post-injection). Background subtraction is applied using perirenal ROIs. Each kidney's corrected counts are expressed as percentage of bilateral total:

SRF (right) = [Counts(right) − Background(right)] / [Total corrected counts] × 100

Depth correction (geometric mean method) improves accuracy for kidneys at different depths (transplant, horseshoe, pelvic).

Clinical Thresholds in Reconstructive Urology

SRF	Interpretation	Clinical Action
45–55%	Normal symmetry	No functional asymmetry
40–44%	Mildly reduced	Monitor; define trend
35–39%	Moderately reduced	Increased surveillance; consider intervention if declining
25–34%	Significantly reduced	Intervention strongly favored if obstruction confirmed
<25%	Severely reduced (functionally solitary contralateral)	Intervention critical; discuss nephrectomy vs. reconstruction
<15%	Near-nonfunctioning	Reconstruction unlikely to recover function; nephrectomy consideration

Serial SRF Trending

A single SRF measurement has limited precision (±3–5% inter-study variability). Decision-making should use:

1. Absolute SRF value relative to thresholds above
2. Trend over serial studies — decline >5% from baseline is clinically significant
3. Correlation with hydronephrosis grade, symptoms, and creatinine

:::info Creatinine Is Insensitive Contralateral compensatory hypertrophy maintains normal serum creatinine until the affected kidney loses >60% of its own function. Do not rely on creatinine to monitor upper tract function in unilateral obstruction — serial MAG3 SRF trending is required. :::

---

5. Indications in Reconstructive Urology

Urethral Stricture — Upper Tract Surveillance

Chronic bladder outlet obstruction from untreated or recurrent stricture elevates voiding pressures, reduces bladder compliance, and transmits elevated pressures to the upper tracts. Upper tract dilation and renal functional loss are well-documented sequelae.

Obtain MAG3 in stricture patients when:

• Bilateral hydronephrosis on ultrasound
• Post-void residual >300 mL chronically
• Recurrent febrile UTI/pyelonephritis
• Creatinine rising without other explanation
• Pre-operatively before complex urethroplasty (establishes baseline)
• Annually in patients managed with recurrent dilation/DVIU without definitive repair

MAG3 over CTU in this setting: CTU exposes patients to radiation and contrast without quantifying function. MAG3 directly measures split renal function and drainage kinetics — the actionable parameters. CTU is complementary for anatomic detail.

Neurogenic Bladder — The McGuire 40 cmH₂O Threshold

McGuire et al. (1981, J Urol) established that end-filling detrusor pressure >40 cmH₂O on urodynamics correlates with high risk of upper tract deterioration in neurogenic bladder patients. This threshold has been validated broadly for adults with spinal cord injury, multiple sclerosis, and other neurogenic etiologies.

Mechanism: Sustained elevated storage pressure transmits retrograde hydrostatic pressure through the ureterovesical junction during filling — even without frank VUR on VCUG — leading to functional obstruction and eventual parenchymal loss.

Obtain MAG3 in neurogenic bladder when:

• Baseline at diagnosis (especially SCI, myelomeningocele)
• Urodynamics demonstrate end-filling pressure >40 cmH₂O
• Annual surveillance in patients with documented poor compliance not yet managed
• After augmentation cystoplasty — to confirm upper tract pressure relief
• Any hydronephrosis on surveillance ultrasound

:::tip Protocol Modification In neurogenic bladder with VUR, ensure bladder catheter is in place and fully drained before and during MAG3. Reflux will appear as renal uptake and invalidate SRF calculations. :::

Ureteral Reconstruction

Pre-operative baseline MAG3 is essential before:

• Ureteroneocystostomy (psoas hitch, Boari flap)
• Ureteroureterostomy
• Ileal ureter substitution
• Buccal mucosal graft ureteroplasty
• Complex ureteral reconstruction after radiation injury

MAG3 answers three pre-operative questions:

1. Does the affected kidney contribute enough function to justify reconstruction vs. nephrectomy?
2. Is the obstruction causing active functional loss (declining SRF trend)?
3. Does the contralateral kidney have sufficient reserve if reconstruction fails?

Post-operative surveillance after ureteral reconstruction:

• MAG3 at 6–12 weeks post-operatively (after ureteral stent removal, typically 4–6 weeks post-op)
• Repeat at 6 months and 12 months
• Annually for 3–5 years
• Any recurrent hydronephrosis on surveillance ultrasound → immediate MAG3

Urinary Diversion Surveillance

Diversion Type	Protocol
Ileal conduit	MAG3 within 3 months of creation (baseline), then annually for life; preferred over ultrasound alone (hydronephrosis after conduit may be "stable" while function silently declines)
Continent catheterizable pouch	Every 6–12 months × 2 years, then annually; higher risk from mucus obstruction and stomal stenosis
Orthotopic neobladder	Annually with pouch emptied by catheterization before study; prompt MAG3 for any hydronephrosis (ureteroenteric stricture 3–10% incidence)

---

6. MAG3 vs. DTPA

Feature	MAG3	DTPA
Renal clearance mechanism	Tubular secretion (OAT)	Glomerular filtration
Extraction fraction per pass	~40–50%	~15–20%
GFR measurement	No (measures ERPF)	Yes (direct GFR surrogate)
Renal-to-background ratio	High	Lower
Performance with GFR <30 mL/min	Excellent	Poor (flat curves)
Renogram curve quality	Superior at all GFR levels	Adequate when GFR >40 only
Radiation dose	~1.5–2.5 mSv	~2.5–3.5 mSv
Preferred for reconstructive urology	Yes — default agent	No
Remaining indications for DTPA	—	Absolute GFR quantification; captopril renography (renovascular HTN)

At most high-volume reconstructive urology centers, MAG3 has effectively replaced DTPA for all functional upper tract evaluations.

---

7. DMSA Renal Cortical Scintigraphy

Tc-99m dimercaptosuccinic acid (DMSA) binds to sulfhydryl groups in proximal tubular cells and is not excreted — providing high-resolution static cortical imaging without a drainage phase. Best agent for cortical scar mapping.

DMSA vs. MAG3: Selection Guide

Clinical Question	Best Agent
Drainage obstruction (T½)	MAG3 with diuretic
Split renal function (general)	MAG3
Cortical scar mapping	DMSA
Acute pyelonephritis (photopenic defect)	DMSA
Post-pyelonephritis scar assessment (at 3–6 months)	DMSA
Duplex kidney moiety differential function	DMSA (careful ROI placement)
Renal pseudotumor vs. column of Bertin	DMSA
Transplant cortical assessment	DMSA

Specific Indications in Reconstructive Urology

1. VUR with suspected renal scarring: DMSA detects cortical scars with sensitivity ~85%, specificity ~93% — superior to IVP and ultrasound. Scarring on DMSA influences the decision for ureteral reimplantation (a scarred kidney may not benefit from anti-reflux repair if functional benefit is minimal).
2. Duplex kidney evaluation: Quantifies differential function of upper and lower moieties, informing choice between upper pole heminephrectomy vs. ureteroureterostomy vs. common sheath reimplantation.
3. Post-pyelonephritis surveillance: At 3–6 months to distinguish permanent scar (fixed cold defect) from transient photopenic defect (resolves on follow-up).
4. Horseshoe or ectopic kidney: DMSA delineates functional cortex with better spatial resolution than MAG3 for aberrantly positioned kidneys before reconstruction.

---

8. Upper Tract Imaging Hierarchy

Primary Question	First-Line Test	Complementary Test	When to Add MAG3
Anatomic obstruction site and level	CT Urogram	Retrograde pyelogram	If function quantification needed or contrast contraindicated
Quantify renal function / SRF	MAG3 renogram	—	First-line
Detect obstruction with function assessment	MAG3 + diuretic	CTU for anatomy	Add CTU if anatomy unclear
Screen for hydronephrosis	Renal ultrasound	—	Upgrade to MAG3 if HN grade ≥3 found
Renal cortical scarring	DMSA	—	—
Stones	Non-contrast CT KUB	—	Add only if functional assessment also needed
Vesicoureteral reflux	VCUG	DMSA for scarring	Add MAG3 if drainage obstruction suspected
Urothelial malignancy	CTU	Ureteroscopy + biopsy	Rarely
Renovascular hypertension	MAG3 captopril renogram	Doppler US	—

Retrograde Pyelogram (RGP) vs. MAG3

These modalities are definitively complementary, not interchangeable:

• RGP: Definitive anatomic test — performed in the OR, under direct urologist control, with immediate endoscopic therapeutic capability
• MAG3: Definitive functional test — split renal function and drainage kinetics

Together they answer all reconstructive planning questions for upper tract pathology.

CT Urogram and MAG3 Sequencing

In patients requiring both anatomic and functional assessment: sequence CTU first, then wait 48 hours before MAG3. Iodinated contrast competes with MAG3 at OAT tubular transporters, reducing renal uptake and distorting SRF calculation if studies are too close together.

---

9. Intervention Thresholds

Obstruction with Preserved Function

T½ >20 min, SRF >40%:

• Confirm adequate hydration and bladder drainage (exclude confounders)
• Repeat in 3–6 months
• If confirmed obstructed on two studies: intervention recommended (pyeloplasty, endopyelotomy, ureteral stent)

Obstruction with Reduced Function

T½ >20 min, SRF 35–40%:

• High priority for intervention
• Trial of decompression: nephrostomy tube placement → repeat MAG3 at 4–6 weeks
• If SRF improves: proceed with definitive reconstruction
• If no improvement: reconstruction less likely to recover function; weigh risk vs. benefit

Near-Nonfunctioning Kidney

SRF <15% with obstruction:

• Nephrostomy decompression trial (4–6 weeks)
• If SRF fails to recover to >20%: nephrectomy vs. continued observation
• Always confirm contralateral SRF >50% before ipsilateral nephrectomy

Functional Loss Without Obstruction

Declining SRF with normal drainage (T½ <10 min):

• Suggests parenchymal disease (infection, scarring, renovascular) independent of obstruction
• DMSA to characterize cortical loss
• Urology + nephrology co-management

---

10. Special Protocols and Pearls

Renal Transplant Protocol

MAG3 is the imaging modality of choice for allograft functional assessment:

Phase	Finding	Interpretation
Phase 1	Delayed/blunted renal peak	Vascular thrombosis or severe rejection
Phase 2	Slow rise, no drainage	ATN (preserved perfusion, poor tubular function)
Phase 2 + Phase 1 abnormal	Poor perfusion AND uptake	Acute rejection
Phase 3	Rising or plateau	Ureteral obstruction at ureteroneocystostomy

Diuretic phase reserved for obstructed-appearing drainage curve. No depth correction needed for anterior superficial allograft.

Pediatric Protocol Differences

• Weight-based tracer dose: 3.7 MBq/kg, minimum 37 MBq
• Furosemide dose: 1 mg/kg IV (max 40 mg)
• F+20 protocol standard in children >1 year
• Infants <1 month: avoid diuretic renogram (immature tubular function); delay to 1–3 months if clinically stable
• Sedation may be required for infants to prevent motion artifact (study duration 30–45 minutes)

Post-Nephrostomy Tube Management

• Clamp tube 2 hours before MAG3 to allow collecting system filling
• Unclamp immediately after Phase 2 during excretory phase
• Document tube position and clamp status on nuclear medicine requisition

Drug Interactions

Drug	Effect on MAG3	Management
ACE inhibitors / ARBs	Reduce GFR (efferent arteriolar dilation)	Hold 3–5 days before routine MAG3; continue intentionally for captopril renography
NSAIDs	Reduce GFR — blunt uptake	Hold 48 hours
Furosemide (chronic oral)	Relative diuretic resistance	Use full IV dose; consider F−15 protocol
Probenecid / organic anions	Compete with MAG3 at OAT transporters	Note on requisition
Iodinated IV contrast (<48 h)	Competes with MAG3 at tubular transporters	Delay MAG3 48 hours after CT

---

11. Ordering Checklist

Before submitting the requisition:

• Clinical indication stated clearly (obstruction evaluation / SRF / post-op surveillance / neurogenic bladder monitoring)
• Relevant prior MAG3 or renal scan results included for comparison
• Current creatinine / eGFR documented
• Active UTI excluded or treated (acute pyelonephritis creates false photopenic defects)
• Interfering medications documented (ACE inhibitors, NSAIDs, recent contrast)
• Bladder drainage specified: void, or catheter required?
• Protocol specified: F+20 standard / F−15 for large capacitance pelvis / F0 for simplified study
• Post-operative: confirm stent status (if present, note clamp plan)

---

12. Reporting Elements

A complete MAG3 renogram report for reconstructive urology should include:

1. Protocol: Agent and dose (MBq), furosemide timing and dose, IV hydration, bladder catheter status
2. Perfusion phase: Symmetric/asymmetric; time to peak; renal/aortic ratio
3. Split renal function (%): Right __ % / Left __ % (method: integral method, 1–2 min window)
4. Drainage curve pattern: O'Reilly classification (Type 1, 2, 3a, 3b, 4)
5. T½ drainage time (min): Right __ / Left __ (from furosemide injection)
6. Collecting system size: Qualitative (mild/moderate/severe hydronephrosis)
7. Interpretation: Obstructed / Equivocal / Unobstructed; functional significance
8. Comparison to prior studies: Trend in SRF

---

References

1. McGuire EJ, Woodside JR, Borden TA, Weiss RM. Prognostic value of urodynamic testing in myelodysplastic patients. J Urol. 1981;126(2):205–209. PMID: 7264526

2. O'Reilly PH, Testa HJ, Lawson RS, et al. Diuresis renography in equivocal urinary tract obstruction. Br J Urol. 1978;50(2):76–80. PMID: 698720

3. O'Reilly PH, Aurell M, Britton K, et al. Consensus on diuresis renography for investigating the dilated upper urinary tract. J Nucl Med. 1996;37(11):1872–1876. PMID: 8917195

4. Sfakianakis GN, Cohen DJ, Braunstein RH, et al. MAG3-F0, MAG3-F15 and MAG3-F20 diuresis renography: the impact of additional parameters on efficacy for the diagnosis of obstructive nephropathy. J Urol. 2000;163(2):448–454. doi:10.1016/S0022-5347(05)67896-4

5. Gordon I, Piepsz A, Sixt R; Eur Assoc Nuclear Medicine. Guidelines for standard and diuretic renogram in children. Eur J Nucl Med Mol Imaging. 2011;38(6):1175–1188. doi:10.1007/s00259-011-1762-5 PMID: 21290165

6. Piepsz A, Colarinha P, Gordon I, et al. Guidelines for 99mTc-DTPA scintigraphy in children with urinary tract obstruction. Eur J Nucl Med. 2001;28(6):BP21–30. PMID: 11431720

7. Taylor A Jr, Eshima D, Fritzberg AR, et al. Comparison of iodine-131 OIH and technetium-99m MAG3 renal imaging in volunteers. J Nucl Med. 1994;35(11):1826–1831. PMID: 8120222

8. Bubeck B, Brandau W, Weber E, et al. Pharmacokinetics of technetium-99m-MAG3 in humans. J Nucl Med. 1990;31(8):1285–1293. PMID: 2174072

9. Boubaker A, Prior JO, Meuwly JY, Bischof-Delaloye A. Radionuclide investigations of the urinary tract in the era of multimodality imaging. J Nucl Med. 2006;47(11):1819–1836. PMID: 17079820

10. Rushton HG, Majd M, Jantausch B, et al. Renal scarring following reflux and nonreflux pyelonephritis in children. J Urol. 1992;147(5):1327–1332. PMID: 1569682

11. Gleeson FV, Gordon I. Imaging in urinary tract infection. Arch Dis Child. 1991;66(11):1282–1283. PMID: 2024747

12. Weld KJ, Dmochowski RR. Effect of bladder management on urological complications in spinal cord injured patients. J Urol. 2000;163(3):768–772. PMID: 10687975

13. Gorin MA, Rowe SP, Carey RM, et al. Prospective evaluation of Tc-99m sestamibi SPECT/CT for the diagnosis of renal oncocytomas and hybrid oncocytic/chromophobe tumors. Eur Urol. 2016;69(3):413–416. PMID: 26542074

14. Santucci RA, Mario LA, McAninch JW. Anastomotic urethroplasty for bulbar urethral stricture: analysis of 168 patients. J Urol. 2002;167(4):1715–1719. doi:10.1016/S0022-5347(05)65182-3